STAT+: Investors double down on Bain-backed startup

STAT PlusNewsletterThe Readout Investors double down on Bain-backed startup FDA’s top gene therapy regulator steps down, Trump’s plan to lower GLP-1 prices, and more biotech news Manage alerts for this article Email this article Share this article By Elaine ChenJune 30, 2026 National Biotech Reporter Elaine Chen[email protected]Elaine’s stories explore the boom in new obesity treatments, new drug payment models, the ways companies are affected by FDA changes, and the emerging psychedelics drug sector. She co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70. Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. We have some news out of Washington, and a look at a company flush with cash. Let’s get to it.Advertisement The need-to-know this morning Abivax disclosed additional data for its experimental ulcerative colitis drug, seemingly allaying at least some of the safety concerns that had flared in recent weeks. FDA’s top gene therapy regulator steps down Vijay Kumar is leaving his role as acting director of the office that reviews cell and gene therapies at the FDA, according to an email obtained by STAT. STAT+ Exclusive Story Already have an account? Log in This article is exclusive to STAT+ subscribers Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts. Already have an account? Log in Monthly $39 Totals $468 per year $39/month Get Started Totals $468 per year Starter $30 for 3 months, then $399/year $30 for 3 months Get Started Then $399/year Annual $399 Save 15% $399/year Get Started Save 15% 11+ Users Custom Savings start at 25%! Request A Quote Request A Quote Savings start at 25%! 2-10 Users $300 Annually per user $300/year Get Started $300 Annually per user View All Plans To read the rest of this story subscribe to STAT+. Subscribe Log In biotechnology, drug development, Drug prices, research Submit a correction requestReprints Elaine Chen National Biotech Reporter Elaine’s stories explore the boom in new obesity treatments, new drug payment models, the ways companies are affected by FDA changes, and the emerging psychedelics drug sector. She co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70. Newsletter Your morning rundown of the science, politics, and money driving biotech today Recommended Biotech June 30, 2026 STAT Plus: AI company Anthropic announces it will begin developing drugs of its own Biotech June 30, 2026 STAT Plus: Anthropic releases Claude Science, a product aimed at researchers, the pharma industry Advertisement Health Tech Newsletter June 30, 2026 STAT Plus: FDA digital leader hints at coming AI policy updates Biotech June 30, 2026 STAT Plus: Abivax seeks to ease safety concerns with new data, boosting shares Exclusive June 29, 2026 STAT Plus: FDA’s top gene therapy regulator is leaving his role Subscriber Picks